Iovance Biotherapeutics, Inc. (IOVA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IOVA Revenue Growth
Revenue Breakdown
IOVA's revenue distribution by segment and geography
By Geography
IOVA Revenue Analysis (2014–2025)
As of May 9, 2026, Iovance Biotherapeutics, Inc. (IOVA) generated trailing twelve-month (TTM) revenue of $285.6 million, reflecting explosive growth of +44.8% year-over-year. The most recent quarter (Q1 2026) recorded $71.4 million in revenue, down 17.7% sequentially.
Looking at the longer-term picture, IOVA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $263.5 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including ADCT (+4.4% YoY), FATE (-51.2% YoY), and CRSP (-88.9% YoY), IOVA has underperformed the peer group in terms of revenue growth. Compare IOVA vs ADCT →
IOVA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IOVACurrent | $286M | +44.8% | - | -153.1% | |
 ADCT | $81M | +4.4% | - | -133.2% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
IOVA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $263.5M | +60.6% | $256.2M | 97.2% | $-403,356,000 | -153.1% |
| 2024 | $164.1M | +13699.0% | $40.1M | 24.4% | $-395,278,000 | -240.9% |
| 2023 | $1.2M | - | $-9,566,000 | -804.5% | $-460,559,000 | -38735.0% |
| 2022 | $0 | - | $0 | - | $-398,878,000 | - |
| 2021 | $0 | - | $0 | - | $-342,703,000 | - |
| 2020 | $0 | - | $0 | - | $-261,937,000 | - |
| 2019 | $0 | - | $-8,123,000 | - | $-206,872,000 | - |
| 2018 | $0 | - | $-956,000 | - | $-128,258,000 | - |
| 2017 | $0 | - | $-952,000 | - | $-92,877,000 | - |
| 2016 | $0 | - | $-978,000 | - | $-53,639,000 | - |
See IOVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IOVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IOVA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIOVA — Frequently Asked Questions
Quick answers to the most common questions about buying IOVA stock.
Is IOVA's revenue growth accelerating or slowing?
IOVA revenue is accelerating at +44.8% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $286M. Growth momentum has increased versus prior periods.
What is IOVA's long-term revenue growth rate?
Iovance Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +44.8% is above this long-term average.
How is IOVA's revenue distributed by segment?
IOVA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.